Common GLP-1 medications include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro, Zepbound), and dulaglutide (Trulicity)
In individuals with well-controlled type 1 diabetes, hyperglucagonaemia may not be evident and may only result from inadequate insulin therapy and/or increased neural activity (reflecting a catabolic stress condition)
1 Thurston RC, El Khoudary SR, Sutton-Tyrrell K, et al
Summary For GLP-1-class research, compound selection depends on which receptor pathways are most relevant to study objectives: Mazdutide: Dual GLP-1/glucagon for glucagon-specific pathway research without GIP Tirzepatide: Dual GLP-1/GIP with FDA approval and extensive published literature Retatrutide: Triple agonist for comprehensive multi-pathway research All three compounds are available at research-grade quality from PeptideStack
A peptide that might last weeks in the fridge could lose significant potency in a single day on the counter